Viking Therapeutics is trading 4.38% down at $27.10 on October 13, 2026, consistent with broader biotech weakness, though available reporting does not establish a direct cause. - Biotech is down 2.01% in regular trading. - No fresh company-specific announcement directly explaining the decline surfaced in available coverage. - The September financing report describes an earlier offering-related drop, not a new catalyst today.